nodes	percent_of_prediction	percent_of_DWPC	metapath
Tramadol—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0571	0.0904	CbGbCtD
Tramadol—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0537	0.085	CbGbCtD
Tramadol—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0537	0.085	CbGbCtD
Tramadol—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0485	0.0769	CbGbCtD
Tramadol—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0407	0.0644	CbGbCtD
Tramadol—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0368	0.0583	CbGbCtD
Tramadol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0276	0.0437	CbGbCtD
Tramadol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0259	0.0411	CbGbCtD
Tramadol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0259	0.0411	CbGbCtD
Tramadol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0235	0.0371	CbGbCtD
Tramadol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0235	0.0371	CbGbCtD
Tramadol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0202	0.0321	CbGbCtD
Tramadol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0197	0.0311	CbGbCtD
Tramadol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0178	0.0281	CbGbCtD
Tramadol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0178	0.0281	CbGbCtD
Tramadol—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0175	0.0278	CbGbCtD
Tramadol—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0165	0.0261	CbGbCtD
Tramadol—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0165	0.0261	CbGbCtD
Tramadol—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0149	0.0236	CbGbCtD
Tramadol—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0149	0.0236	CbGbCtD
Tramadol—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0129	0.0204	CbGbCtD
Tramadol—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0125	0.0198	CbGbCtD
Tramadol—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0113	0.0179	CbGbCtD
Tramadol—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0113	0.0179	CbGbCtD
Tramadol—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0108	0.0172	CbGbCtD
Tramadol—OPRM1—nerve—acquired immunodeficiency syndrome	0.00289	0.0751	CbGeAlD
Tramadol—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00211	0.055	CbGeAlD
Tramadol—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00181	0.0472	CbGeAlD
Tramadol—GRIN3A—nervous system—acquired immunodeficiency syndrome	0.00135	0.0351	CbGeAlD
Tramadol—GRIN3A—central nervous system—acquired immunodeficiency syndrome	0.0013	0.0338	CbGeAlD
Tramadol—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.00118	0.0306	CbGeAlD
Tramadol—GRIN3A—brain—acquired immunodeficiency syndrome	0.00103	0.0269	CbGeAlD
Tramadol—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000952	0.0248	CbGeAlD
Tramadol—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000916	0.0238	CbGeAlD
Tramadol—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000912	0.0237	CbGeAlD
Tramadol—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000889	0.0231	CbGeAlD
Tramadol—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000878	0.0229	CbGeAlD
Tramadol—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000875	0.0228	CbGeAlD
Tramadol—OPRM1—blood—acquired immunodeficiency syndrome	0.000799	0.0208	CbGeAlD
Tramadol—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.00077	0.02	CbGeAlD
Tramadol—OPRD1—brain—acquired immunodeficiency syndrome	0.000727	0.0189	CbGeAlD
Tramadol—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000698	0.0182	CbGeAlD
Tramadol—OPRK1—brain—acquired immunodeficiency syndrome	0.000697	0.0181	CbGeAlD
Tramadol—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000676	0.0176	CbGeAlD
Tramadol—SLC6A4—blood—acquired immunodeficiency syndrome	0.000665	0.0173	CbGeAlD
Tramadol—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000649	0.0169	CbGeAlD
Tramadol—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.000641	0.0167	CbGeAlD
Tramadol—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000625	0.0163	CbGeAlD
Tramadol—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000622	0.0162	CbGeAlD
Tramadol—SLC6A4—lung—acquired immunodeficiency syndrome	0.000583	0.0152	CbGeAlD
Tramadol—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000569	0.0148	CbGeAlD
Tramadol—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000566	0.0147	CbGeAlD
Tramadol—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000548	0.0143	CbGeAlD
Tramadol—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.00054	0.014	CbGeAlD
Tramadol—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.00052	0.0135	CbGeAlD
Tramadol—SLC6A2—lung—acquired immunodeficiency syndrome	0.000513	0.0134	CbGeAlD
Tramadol—OPRM1—brain—acquired immunodeficiency syndrome	0.000496	0.0129	CbGeAlD
Tramadol—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000481	0.0125	CbGeAlD
Tramadol—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000475	0.0124	CbGeAlD
Tramadol—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000463	0.0121	CbGeAlD
Tramadol—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000458	0.0119	CbGeAlD
Tramadol—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000457	0.0119	CbGeAlD
Tramadol—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000453	0.0118	CbGeAlD
Tramadol—HTR2C—brain—acquired immunodeficiency syndrome	0.000435	0.0113	CbGeAlD
Tramadol—CYP2B6—blood—acquired immunodeficiency syndrome	0.000431	0.0112	CbGeAlD
Tramadol—SLC6A4—brain—acquired immunodeficiency syndrome	0.000413	0.0107	CbGeAlD
Tramadol—CYP2B6—vagina—acquired immunodeficiency syndrome	0.0004	0.0104	CbGeAlD
Tramadol—CYP2B6—lung—acquired immunodeficiency syndrome	0.000378	0.00984	CbGeAlD
Tramadol—CHRM3—brain—acquired immunodeficiency syndrome	0.000368	0.00957	CbGeAlD
Tramadol—SLC6A2—brain—acquired immunodeficiency syndrome	0.000363	0.00945	CbGeAlD
Tramadol—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000351	0.00913	CbGeAlD
Tramadol—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.00035	0.00911	CbGeAlD
Tramadol—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000342	0.00889	CbGeAlD
Tramadol—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000337	0.00877	CbGeAlD
Tramadol—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000336	0.00875	CbGeAlD
Tramadol—CYP3A4—blood—acquired immunodeficiency syndrome	0.000326	0.00847	CbGeAlD
Tramadol—CYP2D6—blood—acquired immunodeficiency syndrome	0.00032	0.00834	CbGeAlD
Tramadol—CYP2B6—brain—acquired immunodeficiency syndrome	0.000268	0.00696	CbGeAlD
Tramadol—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000264	0.00688	CbGeAlD
Tramadol—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.00026	0.00677	CbGeAlD
Tramadol—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000255	0.00662	CbGeAlD
Tramadol—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.00025	0.00652	CbGeAlD
Tramadol—CYP2D6—brain—acquired immunodeficiency syndrome	0.000199	0.00517	CbGeAlD
Tramadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000104	0.00323	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000104	0.00321	CbGpPWpGaD
Tramadol—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000103	0.00319	CbGpPWpGaD
Tramadol—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000103	0.00319	CbGpPWpGaD
Tramadol—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000103	0.00318	CbGpPWpGaD
Tramadol—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.0001	0.0031	CbGpPWpGaD
Tramadol—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	9.99e-05	0.00309	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	9.93e-05	0.00307	CbGpPWpGaD
Tramadol—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.64e-05	0.00298	CbGpPWpGaD
Tramadol—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.52e-05	0.00295	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	9.45e-05	0.00293	CbGpPWpGaD
Tramadol—HTR2C—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.4e-05	0.00291	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.38e-05	0.0029	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.35e-05	0.00289	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.3e-05	0.00288	CbGpPWpGaD
Tramadol—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.06e-05	0.00281	CbGpPWpGaD
Tramadol—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.06e-05	0.00281	CbGpPWpGaD
Tramadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.06e-05	0.0028	CbGpPWpGaD
Tramadol—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.01e-05	0.00279	CbGpPWpGaD
Tramadol—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	9e-05	0.00279	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	8.91e-05	0.00276	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.86e-05	0.00274	CbGpPWpGaD
Tramadol—HTR2C—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	8.84e-05	0.00274	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.82e-05	0.00273	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.82e-05	0.00273	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.63e-05	0.00267	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	8.55e-05	0.00265	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.45e-05	0.00262	CbGpPWpGaD
Tramadol—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.44e-05	0.00261	CbGpPWpGaD
Tramadol—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.35e-05	0.00259	CbGpPWpGaD
Tramadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.16e-05	0.00253	CbGpPWpGaD
Tramadol—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.1e-05	0.00251	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.06e-05	0.00249	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.01e-05	0.00248	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	8.01e-05	0.00248	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.95e-05	0.00246	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.95e-05	0.00246	CbGpPWpGaD
Tramadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.94e-05	0.00246	CbGpPWpGaD
Tramadol—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.9e-05	0.00245	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.76e-05	0.0024	CbGpPWpGaD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.67e-05	0.00237	CbGpPWpGaD
Tramadol—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.61e-05	0.00236	CbGpPWpGaD
Tramadol—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.6e-05	0.00235	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.58e-05	0.00235	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.58e-05	0.00235	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.57e-05	0.00234	CbGpPWpGaD
Tramadol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	7.4e-05	0.000249	CcSEcCtD
Tramadol—Anaemia—Lamivudine—acquired immunodeficiency syndrome	7.4e-05	0.000249	CcSEcCtD
Tramadol—Anxiety—Ritonavir—acquired immunodeficiency syndrome	7.4e-05	0.000248	CcSEcCtD
Tramadol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	7.38e-05	0.000248	CcSEcCtD
Tramadol—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	7.37e-05	0.000248	CcSEcCtD
Tramadol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	7.35e-05	0.000247	CcSEcCtD
Tramadol—Pruritus—Abacavir—acquired immunodeficiency syndrome	7.34e-05	0.000247	CcSEcCtD
Tramadol—Fatigue—Indinavir—acquired immunodeficiency syndrome	7.34e-05	0.000246	CcSEcCtD
Tramadol—Anorexia—Delavirdine—acquired immunodeficiency syndrome	7.33e-05	0.000246	CcSEcCtD
Tramadol—Discomfort—Ritonavir—acquired immunodeficiency syndrome	7.33e-05	0.000246	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	7.33e-05	0.000246	CcSEcCtD
Tramadol—Cough—Saquinavir—acquired immunodeficiency syndrome	7.32e-05	0.000246	CcSEcCtD
Tramadol—Angioedema—Lamivudine—acquired immunodeficiency syndrome	7.31e-05	0.000246	CcSEcCtD
Tramadol—Constipation—Indinavir—acquired immunodeficiency syndrome	7.28e-05	0.000244	CcSEcCtD
Tramadol—Pain—Indinavir—acquired immunodeficiency syndrome	7.28e-05	0.000244	CcSEcCtD
Tramadol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	7.27e-05	0.000244	CcSEcCtD
Tramadol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	7.27e-05	0.000244	CcSEcCtD
Tramadol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	7.27e-05	0.000244	CcSEcCtD
Tramadol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	7.26e-05	0.000244	CcSEcCtD
Tramadol—Hypertension—Saquinavir—acquired immunodeficiency syndrome	7.24e-05	0.000243	CcSEcCtD
Tramadol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	7.23e-05	0.000243	CcSEcCtD
Tramadol—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	7.23e-05	0.000243	CcSEcCtD
Tramadol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	7.23e-05	0.000243	CcSEcCtD
Tramadol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	7.22e-05	0.000243	CcSEcCtD
Tramadol—Malaise—Lamivudine—acquired immunodeficiency syndrome	7.22e-05	0.000242	CcSEcCtD
Tramadol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	7.2e-05	0.000242	CcSEcCtD
Tramadol—Nausea—Didanosine—acquired immunodeficiency syndrome	7.2e-05	0.000242	CcSEcCtD
Tramadol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	7.19e-05	0.000242	CcSEcCtD
Tramadol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	7.19e-05	0.000242	CcSEcCtD
Tramadol—Syncope—Lamivudine—acquired immunodeficiency syndrome	7.18e-05	0.000241	CcSEcCtD
Tramadol—Confusional state—Ritonavir—acquired immunodeficiency syndrome	7.17e-05	0.000241	CcSEcCtD
Tramadol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	7.17e-05	0.000241	CcSEcCtD
Tramadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.15e-05	0.00221	CbGpPWpGaD
Tramadol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	7.15e-05	0.00024	CcSEcCtD
Tramadol—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.14e-05	0.00221	CbGpPWpGaD
Tramadol—Chest pain—Saquinavir—acquired immunodeficiency syndrome	7.14e-05	0.00024	CcSEcCtD
Tramadol—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	7.14e-05	0.00024	CcSEcCtD
Tramadol—Myalgia—Saquinavir—acquired immunodeficiency syndrome	7.14e-05	0.00024	CcSEcCtD
Tramadol—Anxiety—Saquinavir—acquired immunodeficiency syndrome	7.12e-05	0.000239	CcSEcCtD
Tramadol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	7.1e-05	0.000238	CcSEcCtD
Tramadol—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	7.09e-05	0.000238	CcSEcCtD
Tramadol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	7.08e-05	0.000238	CcSEcCtD
Tramadol—Discomfort—Saquinavir—acquired immunodeficiency syndrome	7.06e-05	0.000237	CcSEcCtD
Tramadol—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.06e-05	0.00218	CbGpPWpGaD
Tramadol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	7.04e-05	0.000236	CcSEcCtD
Tramadol—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.02e-05	0.00217	CbGpPWpGaD
Tramadol—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	7.01e-05	0.000236	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	7.01e-05	0.000235	CcSEcCtD
Tramadol—Shock—Ritonavir—acquired immunodeficiency syndrome	7e-05	0.000235	CcSEcCtD
Tramadol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	6.99e-05	0.000235	CcSEcCtD
Tramadol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	6.99e-05	0.000235	CcSEcCtD
Tramadol—Cough—Lamivudine—acquired immunodeficiency syndrome	6.99e-05	0.000235	CcSEcCtD
Tramadol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	6.98e-05	0.000235	CcSEcCtD
Tramadol—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	6.98e-05	0.000234	CcSEcCtD
Tramadol—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	6.97e-05	0.000234	CcSEcCtD
Tramadol—Dizziness—Stavudine—acquired immunodeficiency syndrome	6.96e-05	0.000234	CcSEcCtD
Tramadol—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	6.96e-05	0.000234	CcSEcCtD
Tramadol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	6.96e-05	0.000234	CcSEcCtD
Tramadol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	6.94e-05	0.000233	CcSEcCtD
Tramadol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	6.94e-05	0.000233	CcSEcCtD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	6.94e-05	0.00215	CbGpPWpGaD
Tramadol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	6.94e-05	0.000233	CcSEcCtD
Tramadol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	6.93e-05	0.000233	CcSEcCtD
Tramadol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	6.93e-05	0.000233	CcSEcCtD
Tramadol—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	6.91e-05	0.000232	CcSEcCtD
Tramadol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	6.91e-05	0.000232	CcSEcCtD
Tramadol—Confusional state—Saquinavir—acquired immunodeficiency syndrome	6.91e-05	0.000232	CcSEcCtD
Tramadol—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.9e-05	0.00214	CbGpPWpGaD
Tramadol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	6.88e-05	0.000231	CcSEcCtD
Tramadol—Pain—Efavirenz—acquired immunodeficiency syndrome	6.88e-05	0.000231	CcSEcCtD
Tramadol—Constipation—Efavirenz—acquired immunodeficiency syndrome	6.88e-05	0.000231	CcSEcCtD
Tramadol—Rash—Nevirapine—acquired immunodeficiency syndrome	6.88e-05	0.000231	CcSEcCtD
Tramadol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	6.87e-05	0.000231	CcSEcCtD
Tramadol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	6.86e-05	0.00023	CcSEcCtD
Tramadol—Dizziness—Abacavir—acquired immunodeficiency syndrome	6.86e-05	0.00023	CcSEcCtD
Tramadol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	6.84e-05	0.00023	CcSEcCtD
Tramadol—Headache—Nevirapine—acquired immunodeficiency syndrome	6.83e-05	0.000229	CcSEcCtD
Tramadol—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	6.82e-05	0.000229	CcSEcCtD
Tramadol—Chest pain—Lamivudine—acquired immunodeficiency syndrome	6.82e-05	0.000229	CcSEcCtD
Tramadol—Myalgia—Lamivudine—acquired immunodeficiency syndrome	6.82e-05	0.000229	CcSEcCtD
Tramadol—Infection—Saquinavir—acquired immunodeficiency syndrome	6.8e-05	0.000229	CcSEcCtD
Tramadol—Anxiety—Lamivudine—acquired immunodeficiency syndrome	6.79e-05	0.000228	CcSEcCtD
Tramadol—HTR2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.78e-05	0.0021	CbGpPWpGaD
Tramadol—Anorexia—Ritonavir—acquired immunodeficiency syndrome	6.78e-05	0.000228	CcSEcCtD
Tramadol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	6.77e-05	0.000228	CcSEcCtD
Tramadol—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	6.77e-05	0.000227	CcSEcCtD
Tramadol—Urticaria—Indinavir—acquired immunodeficiency syndrome	6.76e-05	0.000227	CcSEcCtD
Tramadol—Shock—Saquinavir—acquired immunodeficiency syndrome	6.74e-05	0.000226	CcSEcCtD
Tramadol—Discomfort—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000226	CcSEcCtD
Tramadol—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.73e-05	0.000226	CcSEcCtD
Tramadol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.73e-05	0.000226	CcSEcCtD
Tramadol—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.72e-05	0.00208	CbGpPWpGaD
Tramadol—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.72e-05	0.00208	CbGpPWpGaD
Tramadol—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.72e-05	0.000226	CcSEcCtD
Tramadol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.72e-05	0.000226	CcSEcCtD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.71e-05	0.00208	CbGpPWpGaD
Tramadol—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.71e-05	0.000225	CcSEcCtD
Tramadol—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.69e-05	0.000225	CcSEcCtD
Tramadol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6.69e-05	0.000225	CcSEcCtD
Tramadol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	6.67e-05	0.000224	CcSEcCtD
Tramadol—Rash—Nelfinavir—acquired immunodeficiency syndrome	6.66e-05	0.000224	CcSEcCtD
Tramadol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	6.65e-05	0.000223	CcSEcCtD
Tramadol—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	6.65e-05	0.000223	CcSEcCtD
Tramadol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	6.65e-05	0.000223	CcSEcCtD
Tramadol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	6.64e-05	0.000223	CcSEcCtD
Tramadol—Rash—Stavudine—acquired immunodeficiency syndrome	6.64e-05	0.000223	CcSEcCtD
Tramadol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	6.63e-05	0.000223	CcSEcCtD
Tramadol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	6.63e-05	0.000223	CcSEcCtD
Tramadol—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	6.63e-05	0.000223	CcSEcCtD
Tramadol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	6.62e-05	0.000222	CcSEcCtD
Tramadol—Headache—Nelfinavir—acquired immunodeficiency syndrome	6.62e-05	0.000222	CcSEcCtD
Tramadol—Headache—Stavudine—acquired immunodeficiency syndrome	6.6e-05	0.000222	CcSEcCtD
Tramadol—Vomiting—Abacavir—acquired immunodeficiency syndrome	6.6e-05	0.000222	CcSEcCtD
Tramadol—Confusional state—Lamivudine—acquired immunodeficiency syndrome	6.59e-05	0.000221	CcSEcCtD
Tramadol—Pain—Delavirdine—acquired immunodeficiency syndrome	6.58e-05	0.000221	CcSEcCtD
Tramadol—Constipation—Delavirdine—acquired immunodeficiency syndrome	6.58e-05	0.000221	CcSEcCtD
Tramadol—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	6.58e-05	0.000221	CcSEcCtD
Tramadol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	6.57e-05	0.000221	CcSEcCtD
Tramadol—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.56e-05	0.00203	CbGpPWpGaD
Tramadol—Rash—Abacavir—acquired immunodeficiency syndrome	6.54e-05	0.00022	CcSEcCtD
Tramadol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	6.53e-05	0.000219	CcSEcCtD
Tramadol—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	6.53e-05	0.000219	CcSEcCtD
Tramadol—Anorexia—Saquinavir—acquired immunodeficiency syndrome	6.53e-05	0.000219	CcSEcCtD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.52e-05	0.00202	CbGpPWpGaD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.52e-05	0.00202	CbGpPWpGaD
Tramadol—Headache—Abacavir—acquired immunodeficiency syndrome	6.5e-05	0.000218	CcSEcCtD
Tramadol—Infection—Lamivudine—acquired immunodeficiency syndrome	6.49e-05	0.000218	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	6.48e-05	0.000218	CcSEcCtD
Tramadol—Nausea—Nevirapine—acquired immunodeficiency syndrome	6.48e-05	0.000218	CcSEcCtD
Tramadol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	6.47e-05	0.000217	CcSEcCtD
Tramadol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	6.44e-05	0.000216	CcSEcCtD
Tramadol—Shock—Lamivudine—acquired immunodeficiency syndrome	6.43e-05	0.000216	CcSEcCtD
Tramadol—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	6.41e-05	0.000215	CcSEcCtD
Tramadol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	6.4e-05	0.000215	CcSEcCtD
Tramadol—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.4e-05	0.00198	CbGpPWpGaD
Tramadol—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	6.4e-05	0.000215	CcSEcCtD
Tramadol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	6.39e-05	0.000215	CcSEcCtD
Tramadol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	6.39e-05	0.000215	CcSEcCtD
Tramadol—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	6.36e-05	0.000214	CcSEcCtD
Tramadol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	6.36e-05	0.000214	CcSEcCtD
Tramadol—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	6.35e-05	0.000213	CcSEcCtD
Tramadol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	6.34e-05	0.000213	CcSEcCtD
Tramadol—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	6.34e-05	0.000213	CcSEcCtD
Tramadol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	6.33e-05	0.000212	CcSEcCtD
Tramadol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	6.32e-05	0.000212	CcSEcCtD
Tramadol—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	6.29e-05	0.000211	CcSEcCtD
Tramadol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	6.27e-05	0.000211	CcSEcCtD
Tramadol—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	6.27e-05	0.000211	CcSEcCtD
Tramadol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	6.26e-05	0.00021	CcSEcCtD
Tramadol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	6.26e-05	0.00021	CcSEcCtD
Tramadol—Nausea—Stavudine—acquired immunodeficiency syndrome	6.25e-05	0.00021	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	6.24e-05	0.00021	CcSEcCtD
Tramadol—Anorexia—Lamivudine—acquired immunodeficiency syndrome	6.23e-05	0.000209	CcSEcCtD
Tramadol—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.21e-05	0.00192	CbGpPWpGaD
Tramadol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	6.19e-05	0.000208	CcSEcCtD
Tramadol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	6.19e-05	0.000208	CcSEcCtD
Tramadol—Nausea—Abacavir—acquired immunodeficiency syndrome	6.16e-05	0.000207	CcSEcCtD
Tramadol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	6.15e-05	0.000207	CcSEcCtD
Tramadol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	6.14e-05	0.000206	CcSEcCtD
Tramadol—HTR2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.14e-05	0.0019	CbGpPWpGaD
Tramadol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	6.13e-05	0.000206	CcSEcCtD
Tramadol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	6.11e-05	0.000205	CcSEcCtD
Tramadol—Asthenia—Indinavir—acquired immunodeficiency syndrome	6.11e-05	0.000205	CcSEcCtD
Tramadol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	6.11e-05	0.000205	CcSEcCtD
Tramadol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	6.1e-05	0.000205	CcSEcCtD
Tramadol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	6.09e-05	0.000205	CcSEcCtD
Tramadol—Pain—Ritonavir—acquired immunodeficiency syndrome	6.08e-05	0.000204	CcSEcCtD
Tramadol—Constipation—Ritonavir—acquired immunodeficiency syndrome	6.08e-05	0.000204	CcSEcCtD
Tramadol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	6.08e-05	0.000204	CcSEcCtD
Tramadol—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	6.08e-05	0.000204	CcSEcCtD
Tramadol—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.06e-05	0.00188	CbGpPWpGaD
Tramadol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	6.05e-05	0.000203	CcSEcCtD
Tramadol—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.05e-05	0.00187	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.05e-05	0.00187	CbGpPWpGaD
Tramadol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000202	CcSEcCtD
Tramadol—Pruritus—Indinavir—acquired immunodeficiency syndrome	6.02e-05	0.000202	CcSEcCtD
Tramadol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.95e-05	0.0002	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.95e-05	0.0002	CcSEcCtD
Tramadol—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.93e-05	0.00184	CbGpPWpGaD
Tramadol—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5.92e-05	0.000199	CcSEcCtD
Tramadol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	5.91e-05	0.000199	CcSEcCtD
Tramadol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	5.91e-05	0.000198	CcSEcCtD
Tramadol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	5.9e-05	0.000198	CcSEcCtD
Tramadol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	5.87e-05	0.000197	CcSEcCtD
Tramadol—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	5.86e-05	0.000197	CcSEcCtD
Tramadol—Constipation—Saquinavir—acquired immunodeficiency syndrome	5.86e-05	0.000197	CcSEcCtD
Tramadol—Pain—Saquinavir—acquired immunodeficiency syndrome	5.86e-05	0.000197	CcSEcCtD
Tramadol—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.84e-05	0.00181	CbGpPWpGaD
Tramadol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	5.82e-05	0.000196	CcSEcCtD
Tramadol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	5.82e-05	0.000196	CcSEcCtD
Tramadol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	5.82e-05	0.000195	CcSEcCtD
Tramadol—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	5.82e-05	0.000195	CcSEcCtD
Tramadol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	5.81e-05	0.000195	CcSEcCtD
Tramadol—Rash—Zidovudine—acquired immunodeficiency syndrome	5.77e-05	0.000194	CcSEcCtD
Tramadol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.77e-05	0.000194	CcSEcCtD
Tramadol—HTR2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.77e-05	0.00179	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.77e-05	0.00179	CbGpPWpGaD
Tramadol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.77e-05	0.000194	CcSEcCtD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.76e-05	0.00178	CbGpPWpGaD
Tramadol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.000193	CcSEcCtD
Tramadol—Headache—Zidovudine—acquired immunodeficiency syndrome	5.73e-05	0.000193	CcSEcCtD
Tramadol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.69e-05	0.000191	CcSEcCtD
Tramadol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.68e-05	0.000191	CcSEcCtD
Tramadol—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.67e-05	0.00019	CcSEcCtD
Tramadol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	5.65e-05	0.00019	CcSEcCtD
Tramadol—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.64e-05	0.00019	CcSEcCtD
Tramadol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.64e-05	0.000189	CcSEcCtD
Tramadol—HTR2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.64e-05	0.00174	CbGpPWpGaD
Tramadol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	5.63e-05	0.000189	CcSEcCtD
Tramadol—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.63e-05	0.000189	CcSEcCtD
Tramadol—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.62e-05	0.000189	CcSEcCtD
Tramadol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.62e-05	0.000189	CcSEcCtD
Tramadol—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.6e-05	0.000188	CcSEcCtD
Tramadol—Constipation—Lamivudine—acquired immunodeficiency syndrome	5.59e-05	0.000188	CcSEcCtD
Tramadol—Pain—Lamivudine—acquired immunodeficiency syndrome	5.59e-05	0.000188	CcSEcCtD
Tramadol—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.57e-05	0.00172	CbGpPWpGaD
Tramadol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	5.52e-05	0.000185	CcSEcCtD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.5e-05	0.0017	CbGpPWpGaD
Tramadol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	5.5e-05	0.000185	CcSEcCtD
Tramadol—HTR2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.49e-05	0.0017	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.47e-05	0.00169	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.45e-05	0.00169	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.45e-05	0.00169	CbGpPWpGaD
Tramadol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	5.44e-05	0.000183	CcSEcCtD
Tramadol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	5.44e-05	0.000183	CcSEcCtD
Tramadol—Nausea—Zidovudine—acquired immunodeficiency syndrome	5.44e-05	0.000183	CcSEcCtD
Tramadol—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	5.41e-05	0.000182	CcSEcCtD
Tramadol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	5.41e-05	0.000182	CcSEcCtD
Tramadol—Vomiting—Indinavir—acquired immunodeficiency syndrome	5.41e-05	0.000182	CcSEcCtD
Tramadol—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	5.38e-05	0.000181	CcSEcCtD
Tramadol—Rash—Indinavir—acquired immunodeficiency syndrome	5.37e-05	0.00018	CcSEcCtD
Tramadol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	5.36e-05	0.00018	CcSEcCtD
Tramadol—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	5.34e-05	0.000179	CcSEcCtD
Tramadol—Headache—Indinavir—acquired immunodeficiency syndrome	5.33e-05	0.000179	CcSEcCtD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.32e-05	0.00165	CbGpPWpGaD
Tramadol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.32e-05	0.000179	CcSEcCtD
Tramadol—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.28e-05	0.00164	CbGpPWpGaD
Tramadol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	5.26e-05	0.000177	CcSEcCtD
Tramadol—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	5.24e-05	0.000176	CcSEcCtD
Tramadol—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.23e-05	0.00162	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.23e-05	0.00162	CbGpPWpGaD
Tramadol—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.22e-05	0.00162	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.19e-05	0.00161	CbGpPWpGaD
Tramadol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	5.19e-05	0.000174	CcSEcCtD
Tramadol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.16e-05	0.000173	CcSEcCtD
Tramadol—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	5.16e-05	0.000173	CcSEcCtD
Tramadol—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.12e-05	0.00159	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.12e-05	0.00159	CbGpPWpGaD
Tramadol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.11e-05	0.000172	CcSEcCtD
Tramadol—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.11e-05	0.00158	CbGpPWpGaD
Tramadol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.1e-05	0.000171	CcSEcCtD
Tramadol—HTR2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.1e-05	0.00158	CbGpPWpGaD
Tramadol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.09e-05	0.000171	CcSEcCtD
Tramadol—Rash—Efavirenz—acquired immunodeficiency syndrome	5.07e-05	0.00017	CcSEcCtD
Tramadol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.07e-05	0.00017	CcSEcCtD
Tramadol—Nausea—Indinavir—acquired immunodeficiency syndrome	5.06e-05	0.00017	CcSEcCtD
Tramadol—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	5.05e-05	0.000169	CcSEcCtD
Tramadol—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	5.04e-05	0.00156	CbGpPWpGaD
Tramadol—Headache—Efavirenz—acquired immunodeficiency syndrome	5.04e-05	0.000169	CcSEcCtD
Tramadol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	5.03e-05	0.000169	CcSEcCtD
Tramadol—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.97e-05	0.00154	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.97e-05	0.00154	CbGpPWpGaD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.96e-05	0.00154	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.95e-05	0.00153	CbGpPWpGaD
Tramadol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.91e-05	0.000165	CcSEcCtD
Tramadol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.89e-05	0.000164	CcSEcCtD
Tramadol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.87e-05	0.000164	CcSEcCtD
Tramadol—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.85e-05	0.0015	CbGpPWpGaD
Tramadol—Rash—Delavirdine—acquired immunodeficiency syndrome	4.85e-05	0.000163	CcSEcCtD
Tramadol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.85e-05	0.000163	CcSEcCtD
Tramadol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.85e-05	0.000163	CcSEcCtD
Tramadol—Headache—Delavirdine—acquired immunodeficiency syndrome	4.82e-05	0.000162	CcSEcCtD
Tramadol—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.81e-05	0.000162	CcSEcCtD
Tramadol—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.8e-05	0.00149	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.78e-05	0.00148	CbGpPWpGaD
Tramadol—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.78e-05	0.00016	CcSEcCtD
Tramadol—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.73e-05	0.00146	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.73e-05	0.00146	CbGpPWpGaD
Tramadol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.71e-05	0.000158	CcSEcCtD
Tramadol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.69e-05	0.000157	CcSEcCtD
Tramadol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.69e-05	0.000157	CcSEcCtD
Tramadol—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.65e-05	0.00144	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.65e-05	0.00144	CbGpPWpGaD
Tramadol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.62e-05	0.000155	CcSEcCtD
Tramadol—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.6e-05	0.00143	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.59e-05	0.00142	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.59e-05	0.00142	CbGpPWpGaD
Tramadol—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.57e-05	0.000154	CcSEcCtD
Tramadol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.53e-05	0.000152	CcSEcCtD
Tramadol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.52e-05	0.000152	CcSEcCtD
Tramadol—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.49e-05	0.00139	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.49e-05	0.00139	CbGpPWpGaD
Tramadol—Rash—Ritonavir—acquired immunodeficiency syndrome	4.49e-05	0.000151	CcSEcCtD
Tramadol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.48e-05	0.000151	CcSEcCtD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.47e-05	0.00138	CbGpPWpGaD
Tramadol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.47e-05	0.00015	CcSEcCtD
Tramadol—Headache—Ritonavir—acquired immunodeficiency syndrome	4.46e-05	0.00015	CcSEcCtD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.44e-05	0.00137	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.39e-05	0.00136	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.39e-05	0.00136	CbGpPWpGaD
Tramadol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.35e-05	0.000146	CcSEcCtD
Tramadol—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.34e-05	0.00134	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	4.34e-05	0.00134	CbGpPWpGaD
Tramadol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.32e-05	0.000145	CcSEcCtD
Tramadol—Rash—Saquinavir—acquired immunodeficiency syndrome	4.32e-05	0.000145	CcSEcCtD
Tramadol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.31e-05	0.000145	CcSEcCtD
Tramadol—Headache—Saquinavir—acquired immunodeficiency syndrome	4.29e-05	0.000144	CcSEcCtD
Tramadol—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	4.29e-05	0.00133	CbGpPWpGaD
Tramadol—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.23e-05	0.000142	CcSEcCtD
Tramadol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.15e-05	0.00014	CcSEcCtD
Tramadol—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.15e-05	0.00128	CbGpPWpGaD
Tramadol—Rash—Lamivudine—acquired immunodeficiency syndrome	4.12e-05	0.000138	CcSEcCtD
Tramadol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.12e-05	0.000138	CcSEcCtD
Tramadol—Headache—Lamivudine—acquired immunodeficiency syndrome	4.09e-05	0.000137	CcSEcCtD
Tramadol—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.08e-05	0.00126	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.08e-05	0.00126	CbGpPWpGaD
Tramadol—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.07e-05	0.000137	CcSEcCtD
Tramadol—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.05e-05	0.00126	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.04e-05	0.00125	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.95e-05	0.00122	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.9e-05	0.00121	CbGpPWpGaD
Tramadol—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.88e-05	0.00013	CcSEcCtD
Tramadol—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.88e-05	0.0012	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.88e-05	0.0012	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.84e-05	0.00119	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.8e-05	0.00118	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.8e-05	0.00118	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.78e-05	0.00117	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.69e-05	0.00114	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.67e-05	0.00114	CbGpPWpGaD
Tramadol—SLC6A4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.63e-05	0.00112	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.54e-05	0.0011	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.51e-05	0.00109	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.51e-05	0.00109	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.49e-05	0.00108	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.48e-05	0.00108	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.47e-05	0.00107	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.45e-05	0.00107	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.45e-05	0.00107	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.42e-05	0.00106	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.4e-05	0.00105	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.37e-05	0.00104	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.33e-05	0.00103	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.33e-05	0.00103	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.26e-05	0.00101	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.26e-05	0.00101	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.23e-05	0.001	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.19e-05	0.000987	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.15e-05	0.000975	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.1e-05	0.000961	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.000953	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.06e-05	0.000946	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	3.02e-05	0.000934	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.01e-05	0.000932	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3e-05	0.000928	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.99e-05	0.000924	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.96e-05	0.000917	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.96e-05	0.000917	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.92e-05	0.000905	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.89e-05	0.000894	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.87e-05	0.000887	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.87e-05	0.000887	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.84e-05	0.000881	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.83e-05	0.000877	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.81e-05	0.000869	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.81e-05	0.000869	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.8e-05	0.000866	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.75e-05	0.000851	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.75e-05	0.000851	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.71e-05	0.000839	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.71e-05	0.000838	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.62e-05	0.000812	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.6e-05	0.000806	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.59e-05	0.000803	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.58e-05	0.0008	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.56e-05	0.000794	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.56e-05	0.000793	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.55e-05	0.000789	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.55e-05	0.000789	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.48e-05	0.000768	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.44e-05	0.000756	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.41e-05	0.000746	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.41e-05	0.000746	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.4e-05	0.000742	CbGpPWpGaD
Tramadol—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.38e-05	0.000737	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.000732	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.25e-05	0.000697	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.23e-05	0.000692	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.22e-05	0.000687	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.17e-05	0.000671	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.14e-05	0.000661	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.1e-05	0.000651	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.09e-05	0.000647	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.06e-05	0.000638	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.06e-05	0.000637	CbGpPWpGaD
Tramadol—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.05e-05	0.000635	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.04e-05	0.000631	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.04e-05	0.000631	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.03e-05	0.000628	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.03e-05	0.000628	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.97e-05	0.00061	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.94e-05	0.0006	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.92e-05	0.000596	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.91e-05	0.000591	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.88e-05	0.000583	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.86e-05	0.000576	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.84e-05	0.00057	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.83e-05	0.000568	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.81e-05	0.000559	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.78e-05	0.000551	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.77e-05	0.000548	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.75e-05	0.000541	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.75e-05	0.000541	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.75e-05	0.000541	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.68e-05	0.000519	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.65e-05	0.000511	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.62e-05	0.0005	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.6e-05	0.000496	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.55e-05	0.00048	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.53e-05	0.000472	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.51e-05	0.000466	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.51e-05	0.000466	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.5e-05	0.000465	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.4e-05	0.000432	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.37e-05	0.000423	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.33e-05	0.000412	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.31e-05	0.000406	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.29e-05	0.0004	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.2e-05	0.000371	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000363	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.15e-05	0.000355	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.13e-05	0.000349	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000344	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000337	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000335	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.03e-05	0.00032	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000312	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.54e-06	0.000295	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.49e-06	0.000294	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	8.79e-06	0.000272	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.06e-06	0.00025	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.02e-06	0.000248	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	7.57e-06	0.000234	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.93e-06	0.000214	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.89e-06	0.000213	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.4e-06	0.000198	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.96e-06	0.000185	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.93e-06	0.000184	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.61e-06	0.000174	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	5.26e-06	0.000163	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.74e-06	0.000147	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.07e-06	0.000126	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.5e-06	0.000109	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.44e-06	0.000106	CbGpPWpGaD
